The value of of MSCT and dynamic contrast-enhanced MRI in differential diagnosis of HCC and IHPCC

Abstract

Abstract: Objective To explore the value of MSCT and dynamic contrast enhanced(DCE)- MRI in differential diagnosis of patients with hepatocellular carcinoma(HCC) and intrahepatic peripheral cholangiocarcinoma(IHPCC). Methods 76 patients with primary liver cancer was selected, both MSCT and DCE-MRI were performed. Results From the study group of 76 patients, 48 patients had HCC and 28 had IHPCC according to histopathological examination. The basic information of HCC patients and IHPCC patients were comparable (P>0.05). The diagnostic coincidence rate of MSCT of 44 cases with HCC was 84.62% (44/52), the diagnostic coincidence rate of MSCT of 13 cases with IHPCC was 54.17% (13/24), and the overall diagnostic coincidence rate was 75.00% (57/76). The diagnostic coincidence rate of MRI of 48 cases with HCC was 92.31% (48/52), the diagnostic coincidence rate of MRI of 16 cases with IHPCC was 66.67% (16/24), and the overall diagnostic coincidence rate was 84.21% (64/76). The results of MSCT combined with MRI, Kappa=0.882, P<0.05, and the combined diagnostic accuracy was 96.05% (73/76).Conclusion Both MSCT and MRI can be used for the differential diagnosis of HCC and IHPCC patients, and the two combined performs better in diagnosis.

Key words: Multi-slice spiral CT, Dynamic contrast-enhanced MRI, Hepatocellular carcinoma, Intrahepatic peripheral cholangiocarcinoma

YIN Rui, YIN Hui-kang, GENG Cheng-jun. The value of of MSCT and dynamic contrast-enhanced MRI in differential diagnosis of HCC and IHPCC[J]. Chinese Hepatolgy, 2023, 28(1): 83-85.

References

[1] 唐亚琴, 卿仁强, 杨松, 等. MRI联合血清ApoB、γ-GT用于原发性肝癌临床价值探讨.中国CT和MRI杂志, 2022, 20(1):110-112.
[2] Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol, 2019, 16(10):589-604.
[3] 姜健, 王维, 崔羽楠, 等. 基于2018版肝脏影像报告及数据系统评估CT及MRI对小于等于3 cm肝细胞性肝癌的诊断价值. 磁共振成像, 2021,12(9):25-2944.
[4] Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment. Cells, 2020, 9(6):1370-1382.
[5] Li F, Li Q, Liu Y, et al. Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017. Eur Radiol, 2020, 30(1):461-470.
[6] Zhao F, Pang G, Li X, et al. Value of perfusion parameters histogram analysis of triphasic CT in differentiating intrahepatic mass forming cholangiocarcinoma from hepatocellular carcinoma. Sci Rep, 2021, 11(1):163-169.
[7] Zhou C, Wang Y, Ma L, et al. Combined hepatocellular carcinoma-cholangiocarcinoma: MRI features correlated with tumor biomarkers and prognosis. Eur Radiol, 2022, 32(1):78-88.
[8] Lee HS, Kim MJ, An C. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI. Eur Radiol, 2019, 29(5):2408-2416.
[9] Chmielewski JP, Bowlby SC, Wheeler FB, et al. CD38 inhibits prostate cancer metabolism and proliferation by reducing cellular NAD(+) pools. Mol Cancer Res, 2018, 16(11): 1687-1700.
[10] Lam JH, Ng HHM, Lim CJ, et al. Expression of CD38 on macrophages predicts improved prognosis in hepatocellular carcinoma. Front Immunol, 2019, 10:2093.
[11] Burel JG, Apte SH, Groves PL, et al. Reduced plasmodium parasite burden associates with CD38⁺ CD4⁺ T cells displaying cytolytic potential and impaired IFN-γ production. PLoS Pathog, 2016, 12(9): e1005839.
[12] Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, Phase Ib Study. J Clin Oncol, 2017, 35(19): 2117-2124.
[13] El-khoueiryi AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet, 2017, 389(10088): 2492-2502.
[14] Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol, 2018, 19(7): 940-952.
[15] Chen L, Diao L, Yang Y, et al. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade. Cancer Discov, 2018, 8(9): 1156-1175.